Black Rock Inc. Oncorus, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.28 - $0.45 $176 - $284	-632 Reduced 0.45%	139,040 $47,000
Q4 2022 Feb 13, 2023	SELL	$0.24 - $0.76 $31,846 - $100,845	-132,692 Reduced 48.72%	139,672 $34,000
Q3 2022 Nov 14, 2022	SELL	$0.85 - $1.65 $5,419 - $10,520	-6,376 Reduced 2.29%	272,364 $231,000
Q2 2022 Aug 12, 2022	SELL	$1.04 - $1.86 $1.09 Million - $1.96 Million	-1,051,796 Reduced 79.05%	278,740 $352,000
Q1 2022 May 12, 2022	SELL	$1.44 - $5.62 $33,801 - $131,918	-23,473 Reduced 1.73%	1,330,536 $2.37 Million
Q4 2021 Feb 10, 2022	BUY	$5.03 - $11.63 $1.25 Million - $2.89 Million	248,560 Added 22.48%	1,354,009 $7.14 Million
Q3 2021 Nov 09, 2021	SELL	$9.29 - $14.27 $16,434 - $25,243	-1,769 Reduced 0.16%	1,105,449 $10.3 Million
Q2 2021 Aug 11, 2021	BUY	$13.3 - $17.3 $14.7 Million - $19.2 Million	1,107,218 New	1,107,218 $15.3 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.